Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Sarah Lindsay

Nurse Practitioner Naples, FL Nurse Practitioner

NPI 1740483676 CMS profile 11184970

11181 Health Park Blvd, 1000, Naples, FL 34110

Open in the dashboard

General payments

$4,541

150 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sarah Lindsay of Naples, FL is reported in the CMS Open Payments database as having received $4,541 across 150 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 91st percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,810 66
2024 General $1,546 54
2023 General $488 19
2022 General $481 9
2021 General $217 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sarah Lindsay
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Sarah Lindsay were reported at $1,810. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Sarah Lindsay Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $217 $135 $40–$426 $132
2022 $481 $152 $48–$470 $149
2023 $488 $166 $54–$529 $160
2024 $1,546 $173 $55–$556 $164
2025 $1,810 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $937 28 payments
  2. Takeda Pharmaceuticals U.S.A., Inc. $458 16 payments
  3. E.R. Squibb & Sons, L.L.C. $254 2 payments
  4. Phathom Pharmaceuticals, Inc. $251 6 payments
  5. Madrigal Pharmaceuticals $207 4 payments
  6. Inspire Medical Systems, Inc. $176 1 payment
  7. Regeneron Healthcare Solutions, Inc. $167 5 payments
  8. GlaxoSmithKline, LLC. $155 5 payments
  9. Janssen Biotech, Inc. $154 7 payments
  10. Grifols USA, LLC $142 6 payments
  11. Other $1,640 70 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $4,510 148 payments
  2. Consulting Fee $19 1 payment
  3. Education $12 1 payment
Products named General payments · program years 2021–2025
  1. ENTYVIO $272 8 payments
  2. UBRELVY $259 4 payments
  3. SKYRIZI $237 8 payments
  4. NURTEC ODT $229 2 payments
  5. RINVOQ $215 7 payments
  6. Inspire Upper Airway Stimulation System $176 1 payment
  7. REZDIFFRA $174 3 payments
  8. DUPIXENT $167 5 payments
  9. QULIPTA $161 3 payments
  10. CUVITRU $143 6 payments
  11. Other $3,381 139 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

902

Median for Nurse Practitioner: 389

Drug cost

$99,548

Median for Nurse Practitioner: $21,885

Branded share of claims

32.8%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Creon Lipase/Protease/Amylase Brand 19 $60,397
Linzess Linaclotide Brand 26 $14,202
Sutab Sod Sulf/Pot Chloride/Mag Sulf Brand 52 $8,332
Pantoprazole Sodium Generic 242 $2,834
Rabeprazole Sodium Generic 53 $2,548
Mesalamine Generic 11 $2,096
Sod Sulf-Potass Sulf-Mag Sulf Sodium, Potassium,mag Sulfates Brand 30 $1,957
Suflave Peg 3350/Sod Sulf,chlr/Pot/Mag Brand 14 $1,738
Cholestyramine Cholestyramine (With Sugar) Brand 28 $1,461
Gavilyte-G Peg3350/Sod Sulf,bicarb,cl/Kcl Brand 70 $960

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 36 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $251
$251 — —
CAMZYOS
  • E.R. Squibb & Sons, L.L.C. $133
$133 — —
DUPIXENT
  • Regeneron Healthcare Solutions, Inc. $130
$130 — —
ZEPOSIA
  • E.R. Squibb & Sons, L.L.C. $121
$121 — —
Prolastin-C Liquid
  • Grifols USA, LLC $88
$88 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 36 with Patron

Records

150 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record